How M.D. was paid
$14.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Yvonne L. Greenstreet, M.D.Chief Executive Officer | $1,404,200 | — | $5,512,500 | $4,363,380 | $3,562,500 | $25,020 | $14,867,600 |
| Jeffrey V. PoultonExecutive Vice President, Chief Financial Officer | $724,400 | — | $3,988,480 | $1,178,220 | $950,300 | $22,400 | $6,863,800 |
| Bryan A. SupranExecutive Vice President, Chief Legal Officer and Secretary | $190,400 | $350,000 | $6,000,430 | — | $214,820 | $90,700 | $6,846,350 |
| Pushkal Garg, M.D.Executive Vice President, Chief Research and Development Officer | $767,900 | — | $3,687,650 | $940,050 | $1,072,500 | $22,400 | $6,490,500 |
| Tolga TangulerExecutive Vice President, Chief Commercial Officer | $698,000 | — | $3,687,650 | $940,050 | $783,200 | $20,120 | $6,129,020 |
What changed and why
- $3BGlobal annual net product revenues increased by 81% over the prior year to nearly $3 billion.
- The company achieved profitability for the first time in its history during 2025.
- $14.9MCEO total compensation was $14,867,600, representing an increase from prior years driven by equity awards.
- 200%Annual incentive bonus payout was 200% based on company performance against pre-established goals.
- 93%93% of CEO total direct compensation was variable and at-risk.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.